why choose us

First received: November 01, 2023

Clinical Trial: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Carcinoma, Non-Small-Cell Lung

Study Type: INTERVENTIONAL


Official Title: SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Plac

Brief Summary: The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC.NSCLC must have a change in a gene called KRAS G12C.Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Read more